Aaron C. Tan

5.8k total citations · 3 hit papers
73 papers, 3.4k citations indexed

About

Aaron C. Tan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Aaron C. Tan has authored 73 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Aaron C. Tan's work include Lung Cancer Treatments and Mutations (25 papers), Cancer Genomics and Diagnostics (14 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Aaron C. Tan is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Cancer Genomics and Diagnostics (14 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Aaron C. Tan collaborates with scholars based in Singapore, Australia and United States. Aaron C. Tan's co-authors include Mustafa Khasraw, David M. Ashley, Henry S. Friedman, Michael D. Malinzak, Giselle Y. López, Daniel S.W. Tan, Daniel Sze, Izabela Konczak, Iqbal Ramzan and Alexander M. Menzies and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Advanced Functional Materials.

In The Last Decade

Aaron C. Tan

70 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Management of glioblastoma: State of the art and future directions

2020 1.4k citations Aaron C. Tan, David M. Ashley et al. profile →
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

2022 423 citations Aaron C. Tan, Daniel S.W. Tan profile →
Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)

2020 363 citations Aaron C. Tan profile →

Peers

Countries citing papers authored by Aaron C. Tan

Since Specialization

Citations

This map shows the geographic impact of Aaron C. Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron C. Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron C. Tan more than expected).

Fields of papers citing papers by Aaron C. Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron C. Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron C. Tan. The network helps show where Aaron C. Tan may publish in the future.

Co-authorship network of co-authors of Aaron C. Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron C. Tan. A scholar is included among the top collaborators of Aaron C. Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron C. Tan. Aaron C. Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Self‐Enhancing Drug Pair‐Driven Selenium Nanotherapeutics Reverses Microglial Pyroptosis Through NLRP3/Caspase‐1 Pathway and Neuronal Apoptosis for Treatment of Spinal Cord Injury 2025 ·Advanced Functional Materials ·Jinggong Liu, (unknown), Aaron C. Tan, Yanxin Du, (unknown), (unknown), Siyuan Rao, Shaohua Chen, Guo‐Yi Su, Tianfeng Chen, Bolai Chen, Yongpeng Lin	4
2	Tibial shaft fractures: current concepts 2025 ·Orthopaedics and Trauma ·Aaron C. Tan, A. J. Rayner, Alastair Robertson	1
3	Transcriptome Deconvolution Reveals Absence of Cancer Cell Expression Signature in Immune Checkpoint Blockade Response 2024 ·Cancer Research Communications ·Yu Amanda Guo, (unknown), Mei Mei Chang, Irfahan Kassam, (unknown), Simone Rizzetto, Aaron C. Tan, Daniel S.W. Tan, Iain Beehuat Tan, Anders J. Skanderup	2
4	Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC 2024 ·Lung Cancer ·Stephanie P.L. Saw, (unknown), Gillianne Lai, Landon L. Chan, (unknown), (unknown), (unknown), (unknown), (unknown), Aaron C. Tan, (unknown), (unknown), (unknown), Quan Sing Ng, Mei‐Kim Ang, Ravindran Kanesvaran, Wan‐Teck Lim, Daniel S.W. Tan, Tony Mok, (unknown)	4
5	The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population 2024 ·Lung Cancer ·(unknown), Nicholas Graves, Aaron C. Tan	5
6	Soluble immune-checkpoint factors: a potential immunotherapy biomarker 2024 ·Journal of Clinical Investigation ·Aaron C. Tan, Sarah Cook, Mustafa Khasraw	1
7	P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study 2023 ·Journal of Thoracic Oncology ·Aaron C. Tan, (unknown), D.-W. Kim, Gwo Fuang Ho, Jcm Ho, Bin-Chi Liao, Lye Mun Tho, (unknown), Thanyanan Reungwetwattana, Yasushi Goto, (unknown), (unknown), (unknown), Herbert H. Loong, Daniel S.W. Tan	0
8	The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice 2023 ·Clinical Cancer Research ·Alex Broom, (unknown), Katherine Kenny, (unknown), Michelle Peterie, (unknown), (unknown), (unknown), Eric Lipp, Aaron C. Tan, Kyle M. Walsh, Brent A. Hanks, Margaret Johnson, Amanda E.D. Van Swearingen, Carey K. Anders, David M. Ashley, Mustafa Khasraw	7
9	Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC 2023 ·International Journal of Molecular Sciences ·Keigo Kobayashi, Aaron C. Tan	7
10	Bystander CD4 ⁺ T cells infiltrate human tumors and are phenotypically distinct 2022 ·OncoImmunology ·Shamin Li, (unknown), (unknown), Si‐Lin Koo, Aaron C. Tan, I‐Ting Chow, William W. Kwok, Iain Beehuat Tan, Daniel S.W. Tan, Yannick Simoni, Evan W. Newell	17
11	Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC 2021 ·Journal of Thoracic Oncology ·Joe Yeong, Lisda Suteja, Yannick Simoni, (unknown), Aaron C. Tan, Hui Hua Li, (unknown), (unknown), (unknown), Sanjna Nilesh Nerurkar, Angela Takano, Eng Huat Tan, Tony Kiat Hon Lim, Evan W. Newell, Daniel S.W. Tan	52
12	Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005) 2021 ·JTO Clinical and Research Reports ·Jiyun Lee, Aaron C. Tan, Siqin Zhou, (unknown), Si‐Yang Maggie Liu, Ken Masuda, Hidetoshi Hayashi, Ullas Batra, Dong‐Wan Kim, Yasushi Goto, Sze Huey Tan, Yi‐Long Wu, Dae Ho Lee, Daniel S.W. Tan, Myung‐Ju Ahn	16
13	FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma 2021 ·Annals of Oncology ·Florentia Dimitriou, Serigne Lo, Aaron C. Tan, Louise Emmett, Rony Kapoor, Matteo S. Carlino, Georgina V. Long, Alexander M. Menzies	22
14	Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer 2020 ·Annals of Oncology ·W. Marston Linehan, Stephen V. Liu, Caroline E. McCoach, Viola W. Zhu, Aaron C. Tan, Satoshi Yoda, Jennifer Peterson, Andrew Do, Kylie Prutisto-Chang, Ibiayi Dagogo‐Jack, Lecia V. Sequist, Lori J. Wirth, Jochen K. Lennerz, Aaron N. Hata, Mari Mino–Kenudson, Valentina Nardi, S.-H.I. Ou, Daniel Shao-Weng Tan, Justin F. Gainor	161
15	FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma 2018 ·Annals of Oncology ·Aaron C. Tan, Louise Emmett, Serigne Lo, (unknown), Rony Kapoor, Matteo S. Carlino, Alexander Guminski, Georgina V. Long, Alexander M. Menzies	104
16	Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock 2017 ·The Journal of Trauma: Injury, Infection, and Critical Care ·(unknown), Federico Aletti, (unknown), Aaron C. Tan, Monica Chang, (unknown), Geert W. Schmid‐Schönbein, Erik B. Kistler	9
17	Immune Checkpoint Inhibitors for Brain Metastases 2017 ·Current Oncology Reports ·Aaron C. Tan, Amy B. Heimberger, Alexander M. Menzies, Nick Pavlakis, Mustafa Khasraw	19
18	Complementary and alternative medicine in diabetes (CALMIND) – a prospective study 2015 ·Journal of Complementary and Integrative Medicine ·Aaron C. Tan, Jenson Mak	10
19	High-Throughput Screening Platform for Anticancer Therapeutic Drug Cytotoxicity 2008 ·Assay and Drug Development Technologies ·(unknown), Rebecca H. Roubin, Aaron C. Tan, Wing Keung Chan, Daniel Sze	24
20	Ongoing adjuvant trials with trastuzumab in breast cancer 2003 ·Seminars in Oncology ·Aaron C. Tan	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact